Double-Targeted cell therapy takes aim at tough leukemia

NCT ID NCT03330691

First seen Dec 15, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This early-phase study tests a personalized cell therapy for children and young adults with a type of leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize two markers (CD19 and CD22) on leukemia cells, to kill them. The main goals are to see if the treatment is safe and if enough cells can be made for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Children's National Medical Center

    Washington D.C., District of Columbia, 20010, United States

  • Children's and Women's Health Centre of British Columbia

    Vancouver, British Columbia, V6H 3V4, Canada

  • Riley Hospital for Children

    Indianapolis, Indiana, 46202, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

Conditions

Explore the condition pages connected to this study.